Skip to main content
SpringerLink
Log in

Uterine/female genital sarcomas

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Choosing the best management of uterine and vulvo-vaginal sarcomas depends on careful histologic review of the pathologic specimen. Prognosis and treatment vary greatly depending on specific histology, grade, and tumor stage. The initial approach to sarcomas of the female genital tract, with the occasional exception of vulvo-vaginal rhabdomyosarcoma, is surgery.

Adjuvant radiation decreases local recurrence rates for uterine sarcomas, but has not been clearly shown to improve overall survival. It is frequently used as adjuvant therapy for resected high-grade or margin-positive vulvo-vaginal sarcomas, and for endometrial stromal sarcomas.

Adjuvant chemotherapy has not been demonstrated to improve survival in vulvo-vaginal sarcomas, with the exception of vulvo-vaginal rhabdomyosarcomas, nor has it been demonstrated to improve survival in uterine sarcomas. Chemotherapy may be used for recurrent or persistent disease. The choice of agent depends on the histologic type of sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Forney JP, Buschbaum HJ: Classifying, staging, and treating uterine sarcomas. Contemp ObGyn 1981, 18:47–69.

    Google Scholar 

  2. Robinson E, Neugent AI, Wylie P: Clinical aspects of postirradiation sarcomas. J Natl Cancer Inst 1988, 80:233.

    Article  PubMed  CAS  Google Scholar 

  3. Meredith RF, Eisert DR, Kaka Z, et al.: An excess of uterine sarcomas after pelvic irradiation. Cancer 1986, 58:2003.

    Article  PubMed  CAS  Google Scholar 

  4. Chauveinc L, Deniaud E, Plancher C, et al.: Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments. Gynecol Oncol 1999, 72:232–237. A recent overview of presentation, stage, recurrence, and survival outcomes in a cohort of 71 uterine sarcoma patients

    Article  PubMed  CAS  Google Scholar 

  5. Berchuck A, Rubin SC, Hoskins WJ, et al.: Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988, 71:845.

    PubMed  CAS  Google Scholar 

  6. Hannigan EV, Gomex IG: Uterine leiomyosarcoma: a review of prognostic clinical and pathologic features. Am J Obstet Gynecol 1979, 134:557.

    PubMed  CAS  Google Scholar 

  7. Peters WA, Kumar NB, Fleming WP, Morley GW: Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol 1984, 63:550–556.

    PubMed  Google Scholar 

  8. Kahanpaa KV, Wahlstrom T, Grohn P, et al.: Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 1986, 67:417.

    PubMed  CAS  Google Scholar 

  9. Leibsohn S, D’Ablaing G, Mishell DR, Schlaerth JB: Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990, 162:968.

    PubMed  CAS  Google Scholar 

  10. Harlow BL, Weiss NS, Lofton S: The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986, 76:399.

    PubMed  CAS  Google Scholar 

  11. Tavassoli FA, Norris HJ: Smooth muscle tumors of the vulva. Obstet Gynecol 1979, 53:213.

    PubMed  CAS  Google Scholar 

  12. Peters WA, Kumar NB, Andersen WA, Morley GW: Primary sarcoma of the adult vagina: a clinicopathologic study. Obstet Gynecol 1985, 65:699–704.

    PubMed  Google Scholar 

  13. Copeland LJ, Gershenson DM, Saul PB, et al.: Sarcoma botryoides of the female genital tract. Obstet Gynecol 1985, 66:262–266.

    PubMed  CAS  Google Scholar 

  14. Silverberg SG, Major FJ, Blessing JA, et al.: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990, 9:1.

    Article  PubMed  CAS  Google Scholar 

  15. Schwartz SM, Thomas DB: The Work Health Organization: collaborative study of neoplasia and steroid contraceptives. Cancer 1989, 64:2487.

    Article  PubMed  CAS  Google Scholar 

  16. Major FJ, Blessing JA, Silverberg SG, et al.: Prognostic factors in early stage uterine sarcomas. A Gynecologic Oncology group study. Cancer 1993, 71:1702–1709.

    PubMed  CAS  Google Scholar 

  17. Goff BA, Rice LW, Fleischhacker D, et al.: Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 1993, 50:105–109.

    Article  PubMed  CAS  Google Scholar 

  18. Sorbe B: Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol 1985, 20:281–289.

    Article  PubMed  CAS  Google Scholar 

  19. Rose PG, Boutselis JG, Sachs L: Adjuvant therapy for stage I uterine sarcoma. Am J Obstet Gynecol 1987, 156:660–662.

    PubMed  CAS  Google Scholar 

  20. Omura GA, Blessing JA, Major F, et al.: A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1985, 3:1240.

    PubMed  CAS  Google Scholar 

  21. Sutton GP, Stehman FB, Michael H, et al.: Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol 1986, 32:156.

    Google Scholar 

  22. Tosi P, Sforza V, Santopietro R: Estrogen receptor content, immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma. Obstet Gynecol 1989, 73:75.

    PubMed  CAS  Google Scholar 

  23. Sutton GP, Blessing JA, Rosenheim N, et al.: Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989, 161:309.

    PubMed  CAS  Google Scholar 

  24. Thigpen JT, Blessing JA, Orr JW Jr, DiSaia PJ: Phase II trial of cisplatin in the treatment ot patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 1986, 70:271–274.

    PubMed  CAS  Google Scholar 

  25. Thigpen JT, Blessing JA, Beecham J, et al.: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991, 9:1962–1966.

    PubMed  CAS  Google Scholar 

  26. Omura GA, Major FJ, Blessing JA, et al.: A randomized study of adriamycin with and without dimethyl triazinomidazole carboxamide in advanced uterine sarcomas. Cancer 1983, 52:626.

    Article  PubMed  CAS  Google Scholar 

  27. Flamant F, Gerbaulet A, Nihoul-Fekete C, et al.: Long-term sequelae of conservative treatment by surgery, brachytherapy, and chemotherapy for vulval and vaginal rhabdomyosarcoma in children. J Clin Oncol 1990, 8:1847–1853.

    PubMed  CAS  Google Scholar 

  28. O’Connor DM, Norris HJ: Mitotically active leiomyomas of the uterus. Hum Pathol 1990, 21:223–227.

    Article  PubMed  CAS  Google Scholar 

  29. Levenback C, Rubin SC, McCormack PM, et al.: Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 1992, 45:202.

    Article  PubMed  CAS  Google Scholar 

  30. Piver MS, Barlow JJ, Wang JJ, et al.: Combined radical surgery, radiation therapy and chemotherapy in infants with vulvo-vaginal embryonal rhabdomyosarcoma. Obstet Gynecol 1973, 42:522–526.

    Article  PubMed  CAS  Google Scholar 

  31. Thigpen JT, Blessing JA, Beecham J, et al.: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas (a Gynecologic Oncology Group study). J Clin Oncol 1991, 9:1962–1966.

    PubMed  CAS  Google Scholar 

  32. Gershenson DM, Kavanagh JJ, Copeland LJ, et al.: High-dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus. Cancer 1987, 59:1264–1267.

    Article  PubMed  CAS  Google Scholar 

  33. Sutton G, Blessing J, McGuire W, et al.: Phase II trial of ifosfamide and mesna in leiomyosarcomas of the uterus. Gynecol Oncol 1990, 36:295.

    Google Scholar 

  34. Sutton G, Blessing J, Barrett R, McGehee R: Phase II trial of ifosfamide and mesna in leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992, 166:556–559.

    PubMed  CAS  Google Scholar 

  35. Muss HB, Bundy BN, DiSaia PH, et al.: Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide. Cancer 1985, 55:1648–1653.

    Article  PubMed  CAS  Google Scholar 

  36. Hensley ML, Schuchter LM, Lindley C, et al.: American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol 1999, 17:3333–3355.

    PubMed  CAS  Google Scholar 

  37. Gershenson DM, Kavanaugh JJ, Copeland LJ, et al.: Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 1987, 5:618.

    PubMed  CAS  Google Scholar 

  38. Thigpen JT, Brady MR, Alvarez RD, et al.: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999, 17:1736–1744.

    PubMed  CAS  Google Scholar 

  39. Piver MS, Rutledge FN, Copeland L, et al.: Uterine endolymphatic stromal myosis: a collaborative study. Obstet Gynecol 1995, 64:173.

    Google Scholar 

  40. Echt G, Jepson J, Steel J, et al.: Treatment of uterine sarcomas. Cancer 1990, 66:35.

    Article  PubMed  CAS  Google Scholar 

  41. Larson B, Silversward C, Nilsson B, Pettersson F: Mixed Mullerian tumors of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 1990, 17:123.

    Article  PubMed  CAS  Google Scholar 

  42. Spanos W, Wharton JT, Gomez L, et al.: Malignant mixed Mullerian tumors of the uterus. Cancer 1984, 53:311.

    Article  PubMed  Google Scholar 

  43. Knocke TH, Weitmann HD, Kucera H, et al.: Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol 1999, 73:389–395. A recent report on the use of radiation in 63 patients with mixed müllerian tumors

    Article  PubMed  CAS  Google Scholar 

  44. Larson B, Silfversward C, Nilsson B, Pettersson F: Mixed Mullerian tumours of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 1990, 17:123–132.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Martee Leigh Hensley MD, MSc

Authors
  1. Martee Leigh Hensley MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hensley, M.L. Uterine/female genital sarcomas. Curr. Treat. Options in Oncol. 1, 161–168 (2000). https://doi.org/10.1007/s11864-000-0061-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0061-6

Keywords

Search

Navigation